Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2012

View Archived Issues

Cardiosphere-derived autologous stem cells tested in patients with myocardial infarction

U.S. scientists design logic-gated DNA nanorobots for targeted drug delivery

Novel USP14 inhibitors presented by Harvard College

Bayer Schering Pharma discloses new soluble guanylate cyclase inhibitors

Boehringer Ingelheim patents new cannabinoid CB2 receptor ligands

Cephalon prepares novel IL-23-binding proteins

Novel antimalarial vaccines designed at Polish university

SGX-202 shows promise in model of gastrointestinal acute radiation syndrome

Gentium responds to EMA's day 120 list of questions for defibrotide MAA

S1 Pharmaceuticals submits IND application for SIP-104

Oral cardiac muscle myosin activator enters phase I trial

Jubilant and Mnemosyne enter collaboration

Full BOLERO-2 study results published

FDA grants priority review to Repligen NDA

Canadian distribution agreement set for tesamorelin

PCI Biotech begins treatment in Amphinex study

Ligand Pharmaceuticals enters new licensing agreement

Nuvo Research provides regulatory update on anesthetic cream

Nippon Kayaku anticancer drugs approved for additional indications in Japan

Preparations begin for European trial of NX-1207

Phase II/III trial to evaluate RLX-030 following acute heart failure

New site added to phase II trial of Telcyta

Novartis seeks line extension for Diovan

Salix begins phase III trial to assess repeated rifaximin treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...